US Congressional Research Service Asks When Pharma Can Challenge Drug Pricing Reform

The Congressional Research Service (CRS), a nonpartisan public policy research institute, released a report asking for more clarity on when lawsuits over upcoming Medicare drug pricing reform can commence. The report comes as industry groups also seek more transparency on time windows as they prepare their legal challenges in advance.

According to Zachary Brennan, “PhRMA said in its comments to CMS that the agency was placing restraints on the disclosure of ‘truthful information about a matter of public significance’ — as the guidance would prohibit manufacturers from disclosing information exchanged verbally or in writing that relates to basic elements of CMS’ MFP decision-making process — which ‘are almost never permissible under the First Amendment.’”

To read more, click here.

(Source: Endpoints News, May 30^th, 2023)